STOCK TITAN

Health In Tech grants CEO 1.5M-share milestone award

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Health In Tech, Inc. (HIT) CEO Sanjay K. Shrestha received restricted Class A stock awards on November 10, 2026: 1,500,000 shares in MC-2, 500,000 shares in MC-3 and 500,000 shares in MC-4. The grants became effective upon stockholder approval of a plan amendment that day. Each tranche is automatically forfeited without consideration unless the issuer’s market capitalization, based on a 10-day volume-weighted average price, exceeds its respective threshold by its deadline: MC-2, $300 million by December 31, 2028; MC-3, $500 million by December 31, 2029; and MC-4, $1 billion by December 31, 2031. After its threshold is met, each tranche vests in 12 equal monthly installments, subject to continued service.

Insider Shrestha Sanjay K
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Class A Common Stock F1 1,500,000 $0.00 $0.00
Grant/Award Class A Common Stock F2 500,000 $0.00 $0.00
Grant/Award Class A Common Stock F3, F4 500,000 $0.00 $0.00
Holdings After Transaction: Class A Common Stock — 7,601,200 shares (Direct)
Holdings Before and After: Class A Common Stock, 5,101,200 to 7,601,200 shares (Direct)
Footnotes (4)
  1. F1. Represents restricted shares of Class A Common Stock (the "MC-2 Tranche") granted pursuant to a Restricted Stock Award Agreement dated October 20, 2026 under the Health In Tech, Inc. Equity Incentive Plan (the "Plan"), the grant of which was contingent upon, and became effective upon, stockholder approval of an amendment to the Plan at the Issuer's 2026 Annual Meeting of Stockholders on November 10, 2026. The shares will be automatically forfeited without consideration unless the Issuer's market capitalization, based on the 10-day volume-weighted average price, exceeds $300 million on or before December 31, 2028 (the "Achievement Date"). Thereafter, the shares vest in twelve equal monthly installments, subject to continued service. If the Achievement Date falls before the 15th calendar day of the month, vesting commences on such 15th day, and if after, commences on the 1st day of the next calendar month.
  2. F2. Represents restricted shares of Class A Common Stock (the "MC-3 Tranche") granted on the same basis as described in footnote (1), except that the market capitalization threshold is $500 million and the deadline is December 31, 2029.
  3. F3. Represents restricted shares of Class A Common Stock (the "MC-4 Tranche") granted on the same basis as described in footnote (1), except that the market capitalization threshold is $1 billion and the deadline is December 31, 2031.
  4. F4. Includes 7,500,000 restricted shares of Class A Common Stock and 101,200 unrestricted shares of Class A Common Stock. Excludes 500,000 restricted shares of Class B Common Stock previously reported. All unvested restricted shares held by the reporting person vest in full upon a Change in Control (as defined in the reporting person's Employment Agreement).
MC-2 restricted Class A award 1,500,000 shares Granted November 10, 2026; threshold of $300 million by December 31, 2028.
MC-2 market-capitalization threshold $300 million Must be exceeded by December 31, 2028, based on a 10-day volume-weighted average price.
MC-3 restricted Class A award 500,000 shares Granted November 10, 2026; threshold of $500 million by December 31, 2029.
MC-3 market-capitalization threshold $500 million Must be exceeded by December 31, 2029, based on a 10-day volume-weighted average price.
MC-4 restricted Class A award 500,000 shares Granted November 10, 2026; threshold of $1 billion by December 31, 2031.
MC-4 market-capitalization threshold $1 billion Must be exceeded by December 31, 2031, based on a 10-day volume-weighted average price.
Restricted Class A shares reported after transaction 7,500,000 shares Included in the post-transaction holdings details.
Unrestricted Class A shares reported after transaction 101,200 shares Included in the post-transaction holdings details.
Restricted Stock Award Agreement technical
"under a Restricted Stock Award Agreement dated October 20, 2026"
A restricted stock award agreement is a legal contract that grants someone company shares that are subject to limits — for example, they may only become fully owned after working at the company for a set time, meeting performance goals, or otherwise satisfying conditions. For investors, these agreements matter because they shape insider incentives, future share dilution when restrictions lift, and company compensation costs; think of it like a gift locked in a box that opens only after certain conditions are met.
Equity Incentive Plan technical
"under the Health In Tech, Inc. Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
10-day volume-weighted average price financial
"based on the 10-day volume-weighted average price"
Achievement Date financial
"on or before December 31, 2028 (the "Achievement Date")"
Change in Control technical
"upon a Change in Control (as defined in the reporting person's Employment Agreement)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did HIT CEO Sanjay K. Shrestha receive in the November 10, 2026 awards?

The three restricted Class A awards covered 1,500,000 MC-2 shares, 500,000 MC-3 shares and 500,000 MC-4 shares.

What market-capitalization targets apply to the HIT CEO's stock awards?

The issuer’s market capitalization, based on a 10-day volume-weighted average price, must exceed $300 million by December 31, 2028 for MC-2, $500 million by December 31, 2029 for MC-3, and $1 billion by December 31, 2031 for MC-4.

How do Sanjay K. Shrestha's HIT stock awards vest?

After a tranche meets its market-capitalization threshold, it vests in 12 equal monthly installments, subject to continued service. If the threshold is met before the 15th calendar day of a month, vesting starts on the 15th; if later, it starts on the first day of the next month. All unvested restricted shares held by Shrestha vest in full upon a Change in Control, as defined in his Employment Agreement.

What HIT shares are listed in Sanjay K. Shrestha's post-transaction holdings?

The post-transaction details list 7,500,000 restricted Class A shares and 101,200 unrestricted Class A shares. They exclude 500,000 restricted Class B shares previously reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shrestha Sanjay K

(Last)(First)(Middle)
701 S. COLORADO AVE
SUITE 1

(Street)
STUART FLORIDA 34994

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Health In Tech, Inc. [ HIT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock11/10/2026A1,500,000(1)A$06,601,200D
Class A Common Stock11/10/2026A500,000(2)A$07,101,200D
Class A Common Stock11/10/2026A500,000(3)A$07,601,200(4)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted shares of Class A Common Stock (the "MC-2 Tranche") granted pursuant to a Restricted Stock Award Agreement dated October 20, 2026 under the Health In Tech, Inc. Equity Incentive Plan (the "Plan"), the grant of which was contingent upon, and became effective upon, stockholder approval of an amendment to the Plan at the Issuer's 2026 Annual Meeting of Stockholders on November 10, 2026. The shares will be automatically forfeited without consideration unless the Issuer's market capitalization, based on the 10-day volume-weighted average price, exceeds $300 million on or before December 31, 2028 (the "Achievement Date"). Thereafter, the shares vest in twelve equal monthly installments, subject to continued service. If the Achievement Date falls before the 15th calendar day of the month, vesting commences on such 15th day, and if after, commences on the 1st day of the next calendar month.
2. Represents restricted shares of Class A Common Stock (the "MC-3 Tranche") granted on the same basis as described in footnote (1), except that the market capitalization threshold is $500 million and the deadline is December 31, 2029.
3. Represents restricted shares of Class A Common Stock (the "MC-4 Tranche") granted on the same basis as described in footnote (1), except that the market capitalization threshold is $1 billion and the deadline is December 31, 2031.
4. Includes 7,500,000 restricted shares of Class A Common Stock and 101,200 unrestricted shares of Class A Common Stock. Excludes 500,000 restricted shares of Class B Common Stock previously reported. All unvested restricted shares held by the reporting person vest in full upon a Change in Control (as defined in the reporting person's Employment Agreement).
/s/ Lori Babcock, as attorney-in-fact for Sanjay Shrestha11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading